Avalo Therapeutics
AVTX
36 hedge funds and large institutions have $133M invested in Avalo Therapeutics in 2019 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 11 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
16% more funds holding
Funds holding: 31 → 36 (+5)
3.39% more ownership
Funds ownership: 54.07% → 57.46% (+3.4%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less capital invested
Capital invested by funds: $135M → $133M (-$1.67M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.2M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.5M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.42M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.29M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$818K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$3.5M |
| 2 |
Millennium Management
New York
|
-$861K |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$665K |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$606K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$329K |
AVTX Hedge Fund Activity: Q2 2019 in Review
36 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q2 2019, worth a combined $133M — down 1.2% from $135M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new AVTX positions and 11 closed out — a net gain of 5 holders — while 10 added to existing stakes and 6 trimmed.
The largest buyer was BlackRock, adding an estimated $6.2M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $3.5M sold.
- 36 institutional investors held Avalo Therapeutics (AVTX) as of Q2 2019, up from 31 in Q1 2019.
- Funds reported $133M of Avalo Therapeutics stock for Q2 2019, down 1.2% quarter-over-quarter.
- 16 funds opened new Avalo Therapeutics positions in Q2 2019 and 11 closed out, a net change of +5 holders.
- The largest Avalo Therapeutics buyer in Q2 2019 was BlackRock, an estimated $6.2M added.
- The largest Avalo Therapeutics seller in Q2 2019 was Eventide Asset Management, an estimated $3.5M sold.
Based on aggregated 13F filings for Q2 2019.